OpRegen® and OpRegen Plus™ New Candidate Treatments for Retinal Disease
OpRegen® and OpRegen-Plus™ are proprietary formulations of human embryonic stem cell (hESC) derived Retinal Pigmented Epithelial (RPE) cells developed to address the high, unmet medical needs of people suffering from age-related macular degeneration (AMD). RPE cells are critical to nourish and support the retina, and when these cells are lost due to disease, patients suffer AMD, leading to severe vision loss and sometimes blindness.
OpRegen provides RPE cells in a suspended form to replace those lost due to AMD and is expected to be among the first hESC-based products to reach clinical trials.
OpRegen Plus provides RPE cells supported within a membrane. This alternative format may provide technical advantages and also may serve as the foundation for our product pipeline.
AMD is the leading cause of blindness and visual impairment in the aging population; 30% of Americans aged 75 and older have some form of AMD. The U.S. Centers for Disease Control and Prevention estimate that about 1.8 million people in the United States have advanced stage AMD and another 7.3 million have an earlier stage and are at risk of vision impairment from the disease. Most people are afflicted with the dry form of the disease, for which there is currently no effective treatment. To learn more about AMD, please visit the National Eye Institute.